Multimodal Data Integration to Predict Severe Acute Oral Mucositis of Nasopharyngeal Carcinoma Patients Following Radiation Therapy
- PMID: 37046693
- PMCID: PMC10093711
- DOI: 10.3390/cancers15072032
Multimodal Data Integration to Predict Severe Acute Oral Mucositis of Nasopharyngeal Carcinoma Patients Following Radiation Therapy
Abstract
(1) Background: Acute oral mucositis is the most common side effect for nasopharyngeal carcinoma patients receiving radiotherapy. Improper or delayed intervention to severe AOM could degrade the quality of life or survival for NPC patients. An effective prediction method for severe AOM is needed for the individualized management of NPC patients in the era of personalized medicine. (2) Methods: A total of 242 biopsy-proven NPC patients were retrospectively recruited in this study. Radiomics features were extracted from contrast-enhanced CT (CECT), contrast-enhanced T1-weighted (cT1WI), and T2-weighted (T2WI) images in the primary tumor and tumor-related area. Dosiomics features were extracted from 2D or 3D dose-volume histograms (DVH). Multiple models were established with single and integrated data. The dataset was randomized into training and test sets at a ratio of 7:3 with 10-fold cross-validation. (3) Results: The best-performing model using Gaussian Naive Bayes (GNB) (mean validation AUC = 0.81 ± 0.10) was established with integrated radiomics and dosiomics data. The GNB radiomics and dosiomics models yielded mean validation AUC of 0.6 ± 0.20 and 0.69 ± 0.14, respectively. (4) Conclusions: Integrating radiomics and dosiomics data from the primary tumor area could generate the best-performing model for severe AOM prediction.
Keywords: acute mucositis; dosiomics; multimodal data integration; nasopharyngeal carcinoma; radiomics.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
CT-based dosiomics and radiomics model predicts radiation-induced lymphopenia in nasopharyngeal carcinoma patients.Front Oncol. 2023 Oct 25;13:1168995. doi: 10.3389/fonc.2023.1168995. eCollection 2023. Front Oncol. 2023. PMID: 37954080 Free PMC article.
-
Normal tissue complication probability model for acute oral mucositis in patients with head and neck cancer undergoing carbon ion radiation therapy based on dosimetry, radiomics, and dosiomics.Radiother Oncol. 2025 Mar;204:110709. doi: 10.1016/j.radonc.2025.110709. Epub 2025 Jan 10. Radiother Oncol. 2025. PMID: 39798699
-
Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation.Lung Cancer. 2024 Mar;189:107507. doi: 10.1016/j.lungcan.2024.107507. Epub 2024 Feb 17. Lung Cancer. 2024. PMID: 38394745
-
MRI-based radiomics models can improve prognosis prediction for nasopharyngeal carcinoma with neoadjuvant chemotherapy.Magn Reson Imaging. 2022 May;88:108-115. doi: 10.1016/j.mri.2022.02.005. Epub 2022 Feb 15. Magn Reson Imaging. 2022. PMID: 35181470
-
Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer.Front Oncol. 2022 Aug 9;12:913683. doi: 10.3389/fonc.2022.913683. eCollection 2022. Front Oncol. 2022. PMID: 36016617 Free PMC article. Review.
Cited by
-
Predictive Factors for Chemoradiation-Induced Oral Mucositis and Dysphagia in Head and Neck Cancer: A Scoping Review.Cancers (Basel). 2023 Dec 4;15(23):5705. doi: 10.3390/cancers15235705. Cancers (Basel). 2023. PMID: 38067408 Free PMC article.
-
Development and verification of a radiomics model to forecast Ki67 index and prognosis in advanced gastric tubular adenocarcinoma.BMC Gastroenterol. 2025 Apr 15;25(1):260. doi: 10.1186/s12876-025-03845-8. BMC Gastroenterol. 2025. PMID: 40234767 Free PMC article.
-
Pain Control in Oral Mucositis According to the Severity Scale: A Narrative Literature Review.J Clin Med. 2025 Jun 24;14(13):4478. doi: 10.3390/jcm14134478. J Clin Med. 2025. PMID: 40648851 Free PMC article. Review.
-
[Performance of multi-modality and multi-classifier fusion models for predicting radiation-induced oral mucositis in patients with nasopharyngeal carcinoma].Nan Fang Yi Ke Da Xue Xue Bao. 2024 Dec 20;44(12):2434-2442. doi: 10.12122/j.issn.1673-4254.2024.12.20. Nan Fang Yi Ke Da Xue Xue Bao. 2024. PMID: 39725633 Free PMC article. Chinese.
-
A multi-center, multi-organ, multi-omic prediction model for treatment-induced severe oral mucositis in nasopharyngeal carcinoma.Radiol Med. 2025 Feb;130(2):161-178. doi: 10.1007/s11547-024-01901-z. Epub 2024 Nov 21. Radiol Med. 2025. PMID: 39570458 Free PMC article.
References
-
- Chen Y.-P., Ismaila N., Chua M.L.K., Colevas A.D., Haddad R., Huang S.H., Wee J.T.S., Whitley A.C., Yi J.-L., Yom S.S., et al. Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J. Clin. Oncol. 2021;39:840–859. doi: 10.1200/JCO.20.03237. - DOI - PubMed
-
- Bossi P., Chan A., Licitra L., Trama A., Orlandi E., Hui E., Halámková J., Mattheis S., Baujat B., Hardillo J., et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;32:452–465. doi: 10.1016/j.annonc.2020.12.007. - DOI - PubMed
-
- You R., Liu Y.-P., Huang P.-Y., Zou X., Sun R., He Y.-X., Wu Y.-S., Shen G.-P., Zhang H.-D., Duan C.-Y., et al. Efficacy and Safety of Locoregional Radiotherapy with Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1345. doi: 10.1001/jamaoncol.2020.1808. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources